Catalym Gmb News Today : Breaking News, Live Updates & Top Stories | Vimarsana

CatalYm to Present Positive New Phase 2a Follow-up Data on GDF-15 Neutralizing Antibody Visugromab in Advanced NSCLC, Urothelial, and Hepatocellular Cancer at the 2024 ASCO Annual Meeting

Oral presentation in "Developmental Therapeutics-Immunotherapy" session on Sunday, June 2, 2024, at 11:30 AM CDT CatalYm today announced that positive new follow-up results from its ongoing "GDFATHER"

Mccormick placeUnited statesPhil lhuilierIgnacio melero bermejoCatalym gmbAlison opalkoTrophic communicationsOncology congressAmerican society of clinical oncologyTed human effector cell relocation phaseAmerican societyClinical oncologyAnnual meetingGrowth differentiationPresentation detailsUniversidad de navarra

CatalYm Presents Positive Phase 2a Outcome for Visugromab in Advanced NSCLC and Urothelial Cancer at the ESMO Immuno-Oncology Congress 2023

CatalYm Presents Positive Phase 2a Outcome for Visugromab in Advanced NSCLC and Urothelial Cancer at the ESMO Immuno-Oncology Congress 2023
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Ignacio meleroPhil lhuillierCatalym gmbOncology congressDepartment of immunologyInternational coordinating investigator profEuropean society for medical oncologyTrophic communicationsObjective response ratesTed human effector cell relocation phaseEuropean societyMedical oncologyImmuno oncology congressGrowth differentiationInternational coordinating investigatorUniversidad de navarra

CatalYm Presents Data at SITC 2023 Annual Meeting Further Unraveling GDF-15-mediated Inhibition of T Cell Adhesion and a New Combination Approach for Visugromab with Bispecific T-Cell Engagers

CatalYm Presents Data at SITC 2023 Annual Meeting Further Unraveling GDF-15-mediated Inhibition of T Cell Adhesion and a New Combination Approach for Visugromab with Bispecific T-Cell Engagers
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

San diegoUnited statesPhil lhuillierChristine schuberth wagnerCatalym gmbTrophic communicationsSociety for immunotherapy of cancerChief scientific officerCentral mediatorT cell engagerTed human effector cell relocationGrowth differentiationPhill huillier

CatalYm commences Dosing in a Phase 2 Study with Visugromab in Combination with Neoadjuvant Immunotherapy in Treatment-naive Muscle Invasive Bladder Cancer Patients

CatalYm commences Dosing in a Phase 2 Study with Visugromab in Combination with Neoadjuvant Immunotherapy in Treatment-naive Muscle Invasive Bladder Cancer Patients
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Catalym gmbPhil lhuilierAndrea necchiPhil lhuillierTrophic communicationsGenitourinary medical oncologyRaffaele hospitalPrincipal investigatorPhill huillierChief executive officerTed human effectorRelocation phaseGrowth differentiationPhill huilier

CatalYm Presents Data at ESMO 2023 Expanding GDF-15 s Role in Checkpoint Therapy Resistance by Inhibition of Myeloid Immune Cell Activation

CatalYm Presents Data at ESMO 2023 Expanding GDF-15 s Role in Checkpoint Therapy Resistance by Inhibition of Myeloid Immune Cell Activation
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Phil lhuilierCatalym gmbChristine schuberth wagnerNature communicationsTrophic communicationsEuropean society for medical oncologyEuropean societyMedical oncologyChief scientific officerTed human effector cell relocationGrowth differentiationPhill huilierStephanie mayAktien sie